1. Inhibition of endothelial proliferation by the somatostatin analogue SOM230;Adams;Clin. Endocrinol. (Oxf.),2004
2. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion;Ambrosi;J. Endocrinol. Invest.,1990
3. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas;Batista;J. Clin. Endocrinol. Metab.,2006
4. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study;Becker;Hepatology,2007
5. Boscaro, M., Petersenn, S., Atkinson, A.B., Bertherat, J., Findling, J., Snyder, P., McBride, K., Reincke, M., Ludlam, W., Gao, B., Melmed, S., Freda, P., Frohman, L., Grossman, A., Biller, B.M.K., Glusman, J.E., 2006. Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease: preliminary safety and efficacy results of a Phase II study. Presented at ENDO 2006 abst OR9-1.